← All trials
NCT06555744
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Jan 31, 2027
- First posted
- Aug 15, 2024
- Last posted
- Nov 6, 2024
- Enrollment
- 145
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zymeworks Inc.Lead sponsor
- Zymeworks Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.